Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CETP | P11597 | 3/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 6/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | DGKA | P23743 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187121 | 0.98 | CYP4F2 (0.45) | CYP4F2CYP4A11ALDH1A1CETPESR1 | |
| SCHEMBL27260326 | 0.88 | CYP4F2 (0.53) | CYP4F2CYP4A11CETPACHENAAA | |
| SCHEMBL16652987 | 0.86 | CYP4F2 (0.51) | CYP4F2CYP4A11CETPACHENAAA | |
| SCHEMBL8411261 | 0.86 | CYP4F2 (0.51) | CYP4F2CYP4A11CETPACHENAAA | |
| SCHEMBL16653040 | 0.86 | CYP4F2 (0.51) | CYP4F2CYP4A11CETPACHENAAA | |
| SCHEMBL14697386 | 0.86 | CYP4F2 (0.51) | CYP4F2CYP4A11CETPACHENAAA | |
| SCHEMBL14697097 | 0.86 | CYP4F2 (0.51) | CYP4F2CYP4A11CETPACHENAAA | |
| SCHEMBL28630718 | 0.86 | CYP4F2 (0.46) | CYP4F2CYP4A11ALDH1A1CETPATM | |
| SCHEMBL2737083 | 0.85 | CYP4F2 (0.48) | CYP4F2CYP4A11ALDH1A1CETPATM | |
| SCHEMBL186379 | 0.85 | CYP4F2 (0.48) | CYP4F2CYP4A11ALDH1A1CETPATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200189999-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2020-06-18 | — | — | US | disclosed |
| US-20190084908-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2019-03-21 | — | — | US | disclosed |
| EP-1701931-B1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20170073286-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073286-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073286-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-9452964-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452964-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452964-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| EP-2402300-B1 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20070155704-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | DASSEUX JEAN-LOUIS H | 2007-06-28 | — | — | US | disclosed |
| US-20060229281-A1 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | ESPERION THERAPEUTIC, INC. | 2006-10-12 | — | — | US | disclosed |
| US-7119221-B2 | treating and preventing a variety of diseases and conditions such as aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic retinopathy, dyslipidemia, dyslipoproteinemia, hypertension, impotence, insulin resistance, peroxisome proliferator activated receptor associated disorders | ESPERION THERAPEUTICS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1701931-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics, Inc. (US) | 2006-09-20 | — | — | EP | disclosed |
| EP-1597223-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005068412-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| US-20040209847-A1 | treating and preventing a variety of diseases and conditions such as aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic retinopathy, dyslipidemia, dyslipoproteinemia, hypertension, impotence, insulin resistance, peroxisome proliferator activated receptor associated disorders | ESPERION THERAPEUTICS, INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040198814-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2004-10-07 | — | — | US | disclosed |
| WO-2004067489-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084908-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | CYP4F2 2014/4885CYP4A11 87/4885ALDH1A1 2139/4885 |
| US-20040209847-A1 | treating and preventing a variety of diseases and conditions such as aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic retinopathy, dyslipidemia, dyslipoproteinemia, hypertension, impotence, insulin resistance, peroxisome proliferator activated receptor associated disorders | PNLIP, APOL1, NR1H3 | CYP4F2 2326/4885CYP4A11 145/4885ALDH1A1 1692/4885 |
| US-20070155704-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | CYP4F2 1045/4885CYP4A11 107/4885ALDH1A1 2141/4885 |
| US-20040198814-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | CYP4F2 1045/4885CYP4A11 107/4885ALDH1A1 2141/4885 |
| US-20200189999-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | CYP4F2 2014/4885CYP4A11 87/4885ALDH1A1 2139/4885 |
| US-20060229281-A1 | e.g. ethyl 11-[1-(t-butoxycarbonyl)cyclopropyl]-2,2-dimethyl-7-oxoundecanoate; peroxisome proliferator activated receptor antagonist; cholesterol reducing, anticarcinogenic, antiinflammatory agent; aging, Alzheimer's Disease, cardiovascular disease, diabetic retinopathy, dyslipidemia, insulin resistance | PNLIP, CYP27A1, GPR119 | CYP4F2 1797/4885CYP4A11 70/4885ALDH1A1 2138/4885 |
| US-20170073286-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | CYP4F2 2014/4885CYP4A11 87/4885ALDH1A1 2139/4885 |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, GPR119 | CYP4F2 1045/4885CYP4A11 107/4885ALDH1A1 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.